Total knee arthroplasty (TKA) can be associated with substantial blood loss, leading to increased morbidity and transfusion rates. The study objective was to evaluate routine use of a thrombin-based topical hemostatic matrix in reducing blood loss and transfusion requirements in primary TKA. 108 patients were enrolled in a prospective, randomized, single-center trial. Patients receiving the hemostatic agent demonstrated a lower mean calculated blood loss (1325.2 ± 464.8 mL vs. control, 1509.3 ± 432.8 mL; P = 0.02), drain output (415.6 ± 202.0 mL vs. control, 579.9 ± 306.7 mL; P = 0.008), and length of stay (3.3 ± 0.8 days vs. control, 3.7 ± 1.1 days; P = 0.03), without a statistically significant difference in mean hemoglobin loss or transfusion requirements. The clinical utility of this hemostatic agent to reduce transfusions after uncomplicated, primary TKA continues to remain unclear.
CoxaPro
> Clinical Library > Welcome to the joint replacement clinical library > Prospective, Randomized Trial to Evaluate Efficacy of a Thrombin-Based Hemostatic Agent in Total Knee Arthroplasty
The Journal of Arthroplasty, Volume 29, Issue 10, 1950 - 1955
Knee
Prospective, Randomized Trial to Evaluate Efficacy of a Thrombin-Based Hemostatic Agent in Total Knee Arthroplasty
Suarez, Juan C. et al.Knee